Overview

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Status:
Active, not recruiting

Trial end date:
2022-09-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Albumin-Bound Paclitaxel
Cetuximab
Gemcitabine
Midazolam
Paclitaxel